Disease · MONDO_0002367
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sunitinib vs Placebo: deaths from any cause | 67 of 306 | 76 of 304 | 610 | NCT00375674 | Trial comparisons |
| Sunitinib vs Placebo: serious adverse events | 67 of 306 | 52 of 304 | 610 | NCT00375674 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease | 2 of 13 | 79 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Serious Adverse Events | 0 of 13 | 47 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Overall Survival | 8 of 13 | 181 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Transplant Related Mortality | 2 of 13 | 40 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: deaths from any cause | 6 of 13 | 124 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Neutrophil and Donor Cell Engraftment | 12 of 13 | 289 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: serious adverse events | 1 of 13 | 53 of 292 | 305 | NCT00303719 | Trial comparisons |
| Arm I (Cabozantinib-s-malate) vs Arm II (Sunitinib Malate): serious adverse events | 39 of 78 | 39 of 72 | 150 | NCT01835158 | Trial comparisons |
| Phase I vs Phase II: serious adverse events | 17 of 48 | 8 of 21 | 69 | NCT00126503 | Trial comparisons |
| Arm I (Bevacizumab) vs Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105): Number of Participants With Overall Response | 1 of 29 | 1 of 30 | 59 | NCT01727089 | Trial comparisons |
| Arm I (Bevacizumab) vs Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105): deaths from any cause | 4 of 29 | 5 of 30 | 59 | NCT01727089 | Trial comparisons |
| Arm I (Bevacizumab) vs Arm II (Bevacizumab, Anti-endoglin Monoclonal Antibody TRC105): serious adverse events | 10 of 29 | 14 of 30 | 59 | NCT01727089 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: deaths from any cause | 3 of 3 | 6 of 44 | 47 | NCT01038778 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: serious adverse events | 0 of 3 | 9 of 44 | 47 | NCT01038778 | Trial comparisons |
| MK2206 vs Everolimus: deaths from any cause | 0 of 29 | 0 of 14 | 43 | NCT01239342 | Trial comparisons |
| MK2206 vs Everolimus: serious adverse events | 7 of 29 | 2 of 14 | 43 | NCT01239342 | Trial comparisons |
| Arm I (Trebananib Monotherapy) vs Arm II (Trebananib and Anti-VEGF Therapy): deaths from any cause | 0 of 17 | 2 of 18 | 35 | NCT01664182 | Trial comparisons |
| Arm I (Trebananib Monotherapy) vs Arm II (Trebananib and Anti-VEGF Therapy): serious adverse events | 10 of 17 | 18 of 18 | 35 | NCT01664182 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002367/comparisons